Department of Prosthetics and Dental Materials, Faculty of Dental Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
MEDFUTURE - Research Center for Advanced Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Int J Nanomedicine. 2018 Jun 8;13:3397-3409. doi: 10.2147/IJN.S167383. eCollection 2018.
Over the last few decades, the incidence of oral cancer has gradually increased, due to the negative influence of environmental factors and also abnormalities within the genome. The main issues in oral cancer treatment consist in surpassing resistance and recurrence. However, continuous discovery of altered signaling pathways in these tumors provides valuable information for the identification of novel gene candidates targeted in personalized therapy. RNA interference (RNAi) is a natural mechanism that involves small interfering RNA (siRNA); this can be exploited in biomedical research by using natural or synthetic constructs for activation of the mechanism. Synthetic siRNA transcripts were developed as a versatile class of molecular tools that have a diverse range of programmable roles, being involved in the regulation of several biological processes, thereby providing the perspective of an alternative option to classical treatment. In this review, we summarize the latest information related to the application of siRNA in oral malignancy together with molecular aspects of the technology and also the perspective upon the delivery system. Also, the emergence of newer technologies such as clustered regularly interspaced short palindromic repeats/Cas9 or transcription activator-like effector nucleases in comparison with the RNAi approach is discussed in this paper.
在过去几十年中,由于环境因素和基因组异常的负面影响,口腔癌的发病率逐渐上升。口腔癌治疗的主要问题在于克服耐药性和复发。然而,这些肿瘤中不断发现改变的信号通路为鉴定新的基因候选物提供了有价值的信息,这些候选物可用于个性化治疗。RNA 干扰 (RNAi) 是一种涉及小干扰 RNA (siRNA) 的自然机制;可以通过使用天然或合成构建体来激活该机制,在生物医学研究中利用这种自然机制。合成 siRNA 转录物已被开发为一类多功能的分子工具,具有多种可编程作用,参与多种生物过程的调节,从而为替代经典治疗提供了一种选择。在这篇综述中,我们总结了 siRNA 在口腔恶性肿瘤中的最新应用信息,以及该技术的分子方面和递药系统的前景。此外,本文还讨论了与 RNAi 方法相比,新型技术(如簇状规则间隔短回文重复序列/Cas9 或转录激活因子样效应物核酸酶)的出现。